Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2024, Vol. 29 ›› Issue (9): 988-1001.doi: 10.12092/j.issn.1009-2501.2024.09.004

Previous Articles     Next Articles

Study on the mechanism of action of Siheifang on zebrafish melanin based on metabolomics and network pharmacology

SU Qihui1, WANG Jing1, LUO Rongrong1, HUANG Yurong1, LI Xin1, WANG Yingli1, JIA Ying2   

  1. 1Shanxi University of Chinese Medicine, College of Traditional Chinese Medicine and Food Engineering, Jinzhong 030619, Shanxi, China; 2Shanxi University of Chinese Medicine, First Clinical College, Taiyuan 030024, Shanxi, China
  • Received:2023-12-25 Revised:2023-11-18 Online:2024-09-26 Published:2024-08-21
  • Supported by:
    中药外用新制剂工艺开发研究(2022SYS23);山西省卫生健康委科研课题(2020096);山西省中医药管理局科研课题(2022ZYYC098)

Abstract:

AIM: To study the mechanism of Siheifang (SHF) in improving pigment deficiency disease (PD) by combining network pharmacology and metabolomics. METHODS: Using zebrafish embryos with pigment deficiency disease induced by 1-phenyl-2-thiourea (PTU) as an animal model, the effects of SHF extract (0.01, 0.02, 0.04 mg/mL) on the morphology, melanin area, tyrosinase activity, and melanin content of zebrafish embryos were analyzed. Ultra high performance liquid chromatography-mass spectrometry (UHPLC-MS) was used to screen differential metabolites and obtain relevant metabolic pathways in the SHF treatment of melanin deficient zebrafish embryos model. Network pharmacology was used to obtain key targets for SHF treatment of PD and conduct KEGG pathway enrichment analysis. Import The identified differential metabolites and SHF PD intersection targets were imported into the Metscape plugin, to establish a "metabolite reaction enzyme gene" network, and search for key metabolites, targets, and metabolic pathways. RESULTS: SHF treatment could increase the formation of zebrafish melanin, activate tyrosinase activity, and increase melanin content. Metabolomics analysis obtained 54 differential metabolites, and metabolic pathway analysis was conducted on these metabolites, involving the biosynthesis of phenylalanine, tyrosine, and tryptophan, glycerol phospholipid metabolism, tyrosine metabolism, linoleic acid metabolism, and aminoacyl tRNA biosynthesis pathways. Network pharmacology had obtained 55 cross targets of components and diseases. KEGG involved pancreatic cancer, TNF, cancer and other signal pathways. The joint analysis of metabolomics and network pharmacology identified four key targets: COMT, CYP1B1, TYR, and ALDH2; three key metabolites: L-tyrosine, homovanllate, L-lysine; three important metabolic pathways: tyrosine metabolism, valine/leucine/isoleucine degradation, and lysine metabolism. CONCLUSION: SHF has a good improvement effect on PD, and combined with metabolomics and network pharmacology, SHF may enhance its influence on the tyrosine metabolism pathway by regulating the metabolite L-tyrosine, thereby promoting the formation of melanin.

Key words: Siheifang, pigmentation deficiency, metabolomics, network pharmacology

CLC Number: